AU1444600A - Methods for inhibiting oxidative modification of proteins - Google Patents

Methods for inhibiting oxidative modification of proteins

Info

Publication number
AU1444600A
AU1444600A AU14446/00A AU1444600A AU1444600A AU 1444600 A AU1444600 A AU 1444600A AU 14446/00 A AU14446/00 A AU 14446/00A AU 1444600 A AU1444600 A AU 1444600A AU 1444600 A AU1444600 A AU 1444600A
Authority
AU
Australia
Prior art keywords
proteins
methods
oxidative modification
inhibiting oxidative
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU14446/00A
Inventor
John Baynes
Billy Hudson
Raja Khalifah
Joelle Onorato
Suzanne Thorpe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Carolina
University of Kansas Medical Center
Original Assignee
University of South Carolina
University of Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Carolina, University of Kansas Medical Center filed Critical University of South Carolina
Publication of AU1444600A publication Critical patent/AU1444600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU14446/00A 1998-10-09 1999-10-08 Methods for inhibiting oxidative modification of proteins Abandoned AU1444600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10379598P 1998-10-09 1998-10-09
US60103795 1998-10-09
PCT/US1999/023702 WO2000022094A2 (en) 1998-10-09 1999-10-08 Methods for inhibiting oxidative modification of proteins

Publications (1)

Publication Number Publication Date
AU1444600A true AU1444600A (en) 2000-05-01

Family

ID=22297071

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14446/00A Abandoned AU1444600A (en) 1998-10-09 1999-10-08 Methods for inhibiting oxidative modification of proteins

Country Status (2)

Country Link
AU (1) AU1444600A (en)
WO (1) WO2000022094A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021516A2 (en) * 1998-10-14 2000-04-20 Kansas University Medical Center Research Institute, Inc. Methods for inhibiting diabetic complications
AU2002237667A1 (en) 2000-11-20 2002-05-27 University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
WO2014125376A2 (en) * 2013-02-15 2014-08-21 Mediterranean Institute For Life Sciences Protein damage in aging and age-related diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4673M (en) * 1965-05-19 1966-12-19
FR7238M (en) * 1968-03-27 1969-09-01
DE2461742C2 (en) * 1974-12-28 1983-01-27 Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt Pyridoxine-5'-phosphoric acid ester derivatives and their preparation and pharmaceuticals containing these compounds
DE3705549A1 (en) * 1987-02-18 1988-09-01 Ulrich Speck USE OF PYRIDOXINE DERIVATIVES IN THE PROPHYLAXIS AND THERAPY OF HYPERLIPIDAEMIA AND ATHEROSCLEROSIS
CA2055990A1 (en) * 1990-11-22 1992-05-23 David G. Schena Phospholipid-vitamin derivatives and methods for preparation thereof
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition

Also Published As

Publication number Publication date
WO2000022094A3 (en) 2001-02-22
WO2000022094A2 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
AU4677399A (en) Inhibitors of H+K+-ATPase
AU2346900A (en) Erythropoietic compounds
EP1143953A3 (en) Method of inhibiting angiogenesis
AU3300599A (en) Per-method designation of security requirements
AU5523098A (en) Arylsulfonamides as phospholipase a2 inhibitors
AU3091599A (en) Method of making dimethylnaphtalenes
AU6229699A (en) Beta-amyloid formation inhibitors
AU6922298A (en) Method for acylation or sulphonation of an aromatic compound
AU2479699A (en) Method for the determination of oxidative stress
AU5551299A (en) Method of identifying proteins
AU2277597A (en) New inhibitors of sh2-mediated processes
AU3444899A (en) Method for the rapid determination of bacteria
AU2354800A (en) Method of protein removal
AU1287100A (en) Peptide inhibitor of browman-birk type
AU5536599A (en) Process for the preparation of neotame
AU2241699A (en) Expression of proteolytically-sensitive peptides
AU6506198A (en) Process for preparation of aromatic compounds
AU5131699A (en) Cryogranulation of activated protein c
AU1444600A (en) Methods for inhibiting oxidative modification of proteins
AU5126298A (en) Inhibition of crib-biting
AUPP385598A0 (en) Purification of antibodies
AU9119998A (en) Method of time-to-talk calculation
AU3678895A (en) Methods of inhibiting endometrial mitoses
AU2619199A (en) Treatment of waxes
AU4282999A (en) Method of identifying antidepressant compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase